Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Amphotericin B releasing nanoparticle topical treatment of Candida spp. in the setting of a burn wound.

Sanchez DA, Schairer D, Tuckman-Vernon C, Chouake J, Kutner A, Makdisi J, Friedman JM, Nosanchuk JD, Friedman AJ.

Nanomedicine. 2014 Jan;10(1):269-77. doi: 10.1016/j.nano.2013.06.002. Epub 2013 Jun 12.

PMID:
23770066
2.

New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp.

Ruiz HK, Serrano DR, Dea-Ayuela MA, Bilbao-Ramos PE, Bolás-Fernández F, Torrado JJ, Molero G.

Int J Pharm. 2014 Oct 1;473(1-2):148-57. doi: 10.1016/j.ijpharm.2014.07.004. Epub 2014 Jul 3.

PMID:
24998510
3.

Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice.

Xu N, Gu J, Zhu Y, Wen H, Ren Q, Chen J.

Int J Nanomedicine. 2011;6:905-13. doi: 10.2147/IJN.S17503. Epub 2011 Apr 28.

4.

Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects.

Charvalos E, Tzatzarakis MN, Van Bambeke F, Tulkens PM, Tsatsakis AM, Tzanakakis GN, Mingeot-Leclercq MP.

J Antimicrob Chemother. 2006 Feb;57(2):236-44. Epub 2005 Dec 16.

PMID:
16361329
5.

Liposomal and lipid-based formulations of amphotericin B.

de Marie S.

Leukemia. 1996 Jun;10 Suppl 2:s93-6. Review.

PMID:
8649062
6.

Amphotericin B-copper(II) complex as a potential agent with higher antifungal activity against Candida albicans.

Chudzik B, Tracz IB, Czernel G, Fiołka MJ, Borsuk G, Gagoś M.

Eur J Pharm Sci. 2013 Aug 16;49(5):850-7. doi: 10.1016/j.ejps.2013.06.007. Epub 2013 Jun 19.

PMID:
23791641
7.

Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.

Fukui H, Koike T, Nakagawa T, Saheki A, Sonoke S, Tomii Y, Seki J.

Int J Pharm. 2003 Nov 28;267(1-2):101-12.

PMID:
14602388
8.

Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.

Tiphine M, Letscher-Bru V, Herbrecht R.

Transpl Infect Dis. 1999 Dec;1(4):273-83. Review.

PMID:
11428998
9.

In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.

Lewis RE, Wiederhold NP, Prince RA, Kontoyiannis DP.

J Antimicrob Chemother. 2006 Feb;57(2):288-93. Epub 2005 Dec 30.

PMID:
16387749
10.

Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins.

Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA.

Antimicrob Agents Chemother. 2002 Jun;46(6):1773-80.

11.

Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation.

Hussain A, Samad A, Singh SK, Ahsan MN, Haque MW, Faruk A, Ahmed FJ.

Drug Deliv. 2016;23(2):642-47. doi: 10.3109/10717544.2014.933284. Epub 2014 Jul 11.

PMID:
25013957
12.

Amphotericin B-silver hybrid nanoparticles: synthesis, properties and antifungal activity.

Tutaj K, Szlazak R, Szalapata K, Starzyk J, Luchowski R, Grudzinski W, Osinska-Jaroszuk M, Jarosz-Wilkolazka A, Szuster-Ciesielska A, Gruszecki WI.

Nanomedicine. 2016 May;12(4):1095-1103. doi: 10.1016/j.nano.2015.12.378. Epub 2016 Jan 7.

PMID:
26772425
13.

Efficacy of a new formulation of amphotericin B in murine disseminated infections by Candida glabrata or Candida tropicalis.

Mariné M, Espada R, Torrado J, Pastor FJ, Guarro J.

Int J Antimicrob Agents. 2009 Dec;34(6):566-9. doi: 10.1016/j.ijantimicag.2009.07.005. Epub 2009 Sep 3.

PMID:
19733036
14.

Mixed micellar nanoparticle of amphotericin B and poly styrene-block-poly ethylene oxide reduces nephrotoxicity but retains antifungal activity.

Han K, Miah MA, Shanmugam S, Yong CS, Choi HG, Kim JA, Yoo BK.

Arch Pharm Res. 2007 Oct;30(10):1344-9.

PMID:
18038914
15.

Poly(L-lactide) Nanoparticles Reduce Amphotericin B Cytotoxicity and Maintain Its In Vitro Antifungal Activity.

Casa DM, Carraro TC, de Camargo LE, Dalmolin LF, Khalil NM, Mainardes RM.

J Nanosci Nanotechnol. 2015 Jan;15(1):848-54.

PMID:
26328449
16.

Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study.

Arrieta AC, Shea K, Dhar V, Cleary JP, Kukreja S, Morris M, Vargas-Shiraishi OM, Ashouri N, Singh J.

Clin Ther. 2010 Feb;32(2):265-71. doi: 10.1016/j.clinthera.2010.02.016.

PMID:
20206784
17.

A novel formulation of solubilised amphotericin B designed for ophthalmic use.

Serrano DR, Ruiz-Saldaña HK, Molero G, Ballesteros MP, Torrado JJ.

Int J Pharm. 2012 Nov 1;437(1-2):80-2. doi: 10.1016/j.ijpharm.2012.07.065. Epub 2012 Aug 4.

PMID:
22890190
18.

Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™.

Italia JL, Sharp A, Carter KC, Warn P, Kumar MN.

PLoS One. 2011;6(10):e25744. doi: 10.1371/journal.pone.0025744. Epub 2011 Oct 6.

19.

In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.

Espada R, Valdespina S, Dea MA, Molero G, Ballesteros MP, Bolás F, Torrado JJ.

J Antimicrob Chemother. 2008 May;61(5):1125-31. doi: 10.1093/jac/dkn048. Epub 2008 Feb 19.

PMID:
18285313
20.

Anti-transferrin receptor-modified amphotericin B-loaded PLA-PEG nanoparticles cure Candidal meningitis and reduce drug toxicity.

Tang X, Liang Y, Zhu Y, Xie C, Yao A, Chen L, Jiang Q, Liu T, Wang X, Qian Y, Wei J, Ni W, Dai J, Jiang Z, Hou W.

Int J Nanomedicine. 2015 Oct 5;10:6227-41. doi: 10.2147/IJN.S84656. eCollection 2015.

Supplemental Content

Support Center